[CAS NO. 64485-93-4] Cefotaximesodium
PRODUCTS SPECIFICATIONS [64485-93-4]
DESCRIPTION [64485-93-4]
Overview
| MDL | MFCD00079073 |
|---|---|
| Molecular Weight | 477.45 |
| Molecular Formula | C16H16N5NaO7S2 |
| SMILES | O=C(C(N12)=C(COC(C)=O)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)O[Na] |
Summary
Cefotaxime (Cefotaxim) sodium, a β-lactamase stable cephalosporin and a third-generation cephalosporin antibiotic , possesses broad-spectrum antibiotic activity against numerous Gram-positive and Gram-negative bacteria [1] [2] [3] [4] [5] .
IC50 & Target
|
β-lactam |
In Vitro
Cefotaxime sodium exhibits an MIC of 0.0625 mg/L for
V. vulnificus
CMCP6
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The combination of ciprofloxacin and cefotaxime is more effective in clearing
V. vulnificus
in vivo than previously used regimens
[4]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female, specific pathogen free, 8-week-old BALB/c mice [4] . |
| Dosage: | 30 mg/kg. |
| Administration: | IP every 6 h. |
| Result: | The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each). |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04168099 | Tanta University |
Spontaneous Bacterial Peritonitis
|
December 1, 2018 | Phase 3 |
| NCT05426499 | Poznan University of Medical Sciences|University at Buffalo|The Greater Poland Cancer Centre |
Population Modeling of Anti-infective Drugs
|
October 1, 2021 | |
| NCT02959957 | Håkan Hanberger|Public Health Agency of Sweden |
Urinary Tract Infections
|
May 20, 2016 | Phase 4 |
| NCT02659033 | Assistance Publique - Hôpitaux de Paris |
Emergence of Bacterial Resistance to Antibiotics
|
March 2016 | Phase 3 |
| NCT01551394 | PENTA Foundation|Chiesi Farmaceutici S.p.A. |
Sepsis
|
September 2012 | Phase 3 |
| NCT03198819 | Yuzuncu Y?l University |
Postoperative Infection Rates
|
August 2016 | |
| NCT01059890 | Poitiers University Hospital |
Bacterial Infection|Brain Injury
|
September 2009 | Phase 1 |
| NCT02560207 | University Medical Center Groningen |
Critically Ill
|
November 2015 | Phase 4 |
| NCT02388035 | Dr Ahmed Ali Elbaz|Nasser Institute For Research and Treatment |
Spontaneous Bacterial Peritonitis
|
March 2015 | Not Applicable |
| NCT01820026 | University of Roma La Sapienza |
Cirrhosis
|
December 2012 | Phase 4 |
| NCT00469430 | Göteborg University |
Appendicitis
|
May 2006 | Phase 2 |
| NCT03922919 | Centre Hospitalier Universitaire de Besancon |
Infectious Disease - Resistant Enterobacteriaceae (Diagnosis)
|
April 3, 2018 | Phase 4 |
| NCT00187655 | University of California, San Francisco |
Focus Groups
|
January 2004 | Phase 1 |
| NCT02443285 | Tanta University |
Primary Bacterial Peritonitis
|
January 2015 | Phase 3 |
| NCT05427747 | Assiut University |
Spontaneous Bacterial Peritonitis
|
January 1, 2023 | Phase 4 |
| NCT04839653 | MEDSI Clinical Hospital 1, ICU |
Pneumonia, Ventilator-Associated|Pneumonia|Bloodstream Infection|Sepsis|Respiratory Distress Syndrome|Respiratory Tract Infections|Critical Illness
|
May 1, 2021 | Not Applicable |
| NCT03903783 | Groupe Hospitalier Paris Saint Joseph |
Infection, Bacterial
|
April 30, 2019 | Not Applicable |
| NCT01265173 | Korea University |
SBP|Liver Cirrhosis
|
April 2007 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 50 mg/mL ( 104.72 mM ; Need ultrasonic)
DMSO : 45 mg/mL ( 94.25 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.0945 mL | 10.4723 mL | 20.9446 mL |
| 5 mM | 0.4189 mL | 2.0945 mL | 4.1889 mL |
| 10 mM | 0.2094 mL | 1.0472 mL | 2.0945 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (209.45 mM); Clear solution; Need ultrasonic
-
2.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (5.24 mM); Clear solution
-
3.
-
4.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (4.36 mM); Suspended solution; Need ultrasonic
References
- [1] Woodfield JC, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9.
- [2] Scholz H, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7.
- [3] E L Francke, et al. Use of cefotaxime, a beta-lactamase stable cephalosporin, in the therapy of serious infections, including those due to multiresistant organisms. Am J Med. 1981 Sep;71(3):435-42.
- [4] Gums JG, et al. Differences between ceftriaxone and cefotaxime: microbiological inconsistencies. Ann Pharmacother. 2008 Jan;42(1):71-9.
Synonyms